abstract |
The present disclosure provides anti-inflammatory extracellular vesicles (EVs) derived from ex vivo -cultured human suppressive immune cells, e.g., M2 macrophages. Such EVs are useful in the treatment of diseases such as amyotrophic lateral sclerosis (AES), Alzheimer's disease, and other neurological diseases, as well as inflammatory and autoimmune diseases or dysfunctions. |